GLPwatch
Victoza for Alcohol use disorder
liraglutide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCVictoza (liraglutide) is not FDA-approved for alcohol use disorder, and any use for this condition is off-label or investigational. Research in animals suggests liraglutide may reduce alcohol consumption and related effects, but these findings have not been confirmed in human trials.
AI summary of the sources below.
| Drug | Victoza (liraglutide) |
|---|---|
| Condition | Alcohol use disorder |
| Approval status | Investigational / off-label |
| Research papers | 5 |
Victoza is not FDA-approved for alcohol use disorder; the research below reflects investigational or off-label study only.
Research on liraglutide for alcohol use disorder (5)
- The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents.
- Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder.
- Liraglutide Reduces Alcohol Consumption, Anxiety, Memory Impairment, and Synapse Loss in Alcohol Dependent Mice.
- Liraglutide 3.0 mg once daily for the treatment of overweight and obesity in patients hospitalised at a forensic psychiatric department: A 26-week open-label feasibility study.
- A septal inhibitory circuit constrains alcohol reward and mediates liraglutide's suppressive effects on alcohol intake in mice.